BG8 LewisY

IHC of BG8 LewisY on an FFPE Lung Adenocarcinoma Tissue

Specification Sheets
Safety Data Sheet

SDS

Intended Use For In Vitro Diagnostic Use
Summary and Explanation Blood group antigens have been examined as potential discriminators between Pulmonary Adenocarcinoma (PACA) and Epithelioid Mesothelioma (EM). LewisY is the only one of these that appears to have some merit. BG8 is raised from the SK-LU-3 lung cancer line and is able to distinguish between PACA and EM. Studies of 231 cases of PACA and 197 cases of EM have shown that sensitivity and specificity for PACA were both 93%. It has been reported that sensitivity of nonmesothelial antigens for Adenocarcinoma is organ dependent, with BG8 Lewis performing at 98% in the breast cancer group, and 100% in the lung cancer group. The specificity of the nonmesothelial (non-EM) antigens for adenocarcinoma was 98% for BG8.
It has been concluded using logical regression analysis that a three-antibody immunohistochemical panel including Calretinin, BG8, and MOC-31 would provide 96% sensitivity and specificity for distinguishing EM from Adenocarcinoma in a variety of sources (lung, ovary, breast, stomach).
Antibody Type Mouse Monoclonal Clone F3
Isotype IgM Reactivity Paraffin, Frozen
Localization Cytoplasmic, Membranous Control Placenta, Tonsil, Pancreas, Cervix, Bladder TCC, Lung Adenocarcinoma
Presentation BG8 LewisY is an antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.
Availability
Catalog No. Antibody Type Dilution Volume/QTY
BSB 6373 Prediluted Ready-To-Use 3.0 ml
BSB 6374 Prediluted Ready-To-Use 7.0 ml
BSB 6375 Prediluted Ready-To-Use 15.0 ml
BSB 6376 Concentrated 1:10-1:50 0.1 ml
BSB 6377 Concentrated 1:10-1:50 0.5 ml
BSB 6378 Concentrated 1:10-1:50 1.0 ml
BSB 6379 Control Slides 5
Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.
Related Products